2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

Albert C.H. Yu

Session 12 – Asian Opportunities & Collaborations
Date: 24 July (Friday) 12:20 – 13:50 (GMT+8)
Venue: 701EF, 7F, TaiNEX2 / Online event platform


Albert C.H. Yu

Chairman
Hong Kong Biotechnology Organization



Albert Cheung-Hoi Yu is Professor of the Neuroscience Research Institute, at Peking University. He received his PhD from the University of Saskatchewan, Canada. He then worked at UCSF, Stanford University, Hong Kong University of Science and Technology before Peking University. His research focuses on neurosciences and biotechnology. Recently, he focuses on a BioRadar™ System development. His innovations have granted more than 69 patents worldwide. He has edited 5 books and over 170 peer-reviewed scientific articles.

Professor Yu has served on numerous committees and boards. He is the recipient of the Hong Kong Award for Industry - Technology Achievement Award, China Medical Science and Technology Award, Asian Knowledge Management Award - Leadership, Best Practices Award - Asia Pacific Product Difference Excellence Award for In-Vitro Diagnostics, China Industry-University-Research-Institute Collaboration and Innovation Award, etc. Due to his contribution to the community, he was appointed as Justice of the Peace in Hong Kong. He is currently serving as Chairmen of Hong Kong Biotechnology Organization, Hai Kang Life Corporation, Hong Kong Council for Testing and Certification, Biotechnology Committee of the Chinese Manufacturers’ Association of Hong Kong, Guangdong-Hong Kong-Macao Greater Bay Area Biotechnology Alliance; Director of Asia Fund for Cancer Research; Member of the Henan Provincial Committee of the Chinese People’s Political Consultative Conference; Vice Chairman of Hong Kong-Taiwan Youth Exchange Promotion Association. The Board of Trustees of the Gordon Research Conferences. He was a former Director of Hong Kong Science and Technology Parks; former Vice President of Chinese Neuroscience Society and President of Beijing Neuroscience Society. He has extensive experience in chairing and organizing international conferences. Every effort he spent is to accelerate scientific blossom in Hong Kong, China and Asia.He is now organizing BIOHK2021. It will be a comprehensive event including EXHIBITION, CONFERENCE & PITCH SESSIONS, ONE2ONE PARTNERING which provide a global platform for exploring the potential and limitless biotech opportunities sprouting in Hong Kong and allow networking between leading biotech and health industry practitioners from around the globe.


Speech title & Synopsis

The path of Hong Kong towards an International Innovation Hub

Hong Kong is at the center of converging goals and visions between key regional and global industry, finance, academic, research and innovation sectors; giving rise to an excellent opportunity to capitalize on Hong Kong’s position as a globally strategic hub for biotech.
 
Hong Kong, often considered the gateway to China due to its unique status as a special administrative region, offers a rich source of opportunities for overseas investors looking to capitalize on the continued growth of the Greater Bay Area – a scheme initiated by the Chinese government to link Hong Kong and 10 other cities along the Pearl River Estuary and form an international technology and innovation center rivalling that of Silicon Valley.
 
With its strong exposure and international integration, Hong Kong has become the go-to stepping stone for Chinese companies looking to expand abroad. New listing rules adopted by the Hong Kong Stock Exchange (HKEX) allows pre-revenue biotech companies to be listed on the exchange. A first in Asia, it ensures more capital can flow freely towards a sector that’s been largely deprived in the region until recently. As of May 1, 2019, of the 7 biotech companies that completed their IPOs since the new listing rule, almost half have experienced a share price increase upwards of 65% from its issuance price. As such, owing to its geopolitical advantage, its large number of world class universities and its position as the No. 1 biotech IPO market in Asia, Hong Kong has the potential to be at the epicenter of Asia’s biotech revolution.